<DOC>
	<DOCNO>NCT01037127</DOCNO>
	<brief_summary>MEK113583 Phase II open-label , multi-site study investigate objective response rate , safety , pharmacokinetics GSK1120212 subject BRAF mutation-positive melanoma previously treat without BRAF inhibitor . GSK1120212 potent highly selective inhibitor MEK activation kinase activity .</brief_summary>
	<brief_title>Study Determine Effectiveness GSK1120212 BRAF Mutation-positive Melanoma Previously Treated With Without BRAF Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Metastatic cutaneous melanoma previously treat : ( Cohort A ) BRAF inhibitor either without prior therapy . ( Cohort B ) least 1 prior chemotherapy immunotherapy , without treatment BRAF inhibitor . Documented positive BRAF mutation ( V600E , V600K , V600D ) . Subjects must provide archived tumor tissue undergo fresh tumor biopsy prior enrollment . The subject must radiographically measurable tumor . The subject able carry daily life activity without significant difficulty ( ECOG performance status score 0 1 ) . Able swallow retain oral medication . Sexually active subject must use acceptable method contraception course study . Adequate organ system function blood cell count . The subject major surgery receive certain type cancer therapy within 21 day start study . Previous treatment MEK inhibitor . Current use prohibit medication list protocol . Uncontrolled glaucoma . Brain metastasis , unless previously treat surgery stereotactic radiosurgery , disease stable least 2 month prior enrollment . Current severe uncontrolled systemic disease . History clinically significant heart , lung , eye/vision problem . Significant unresolved side effect previous anticancer therapy . The subject pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>GSK1120212</keyword>
	<keyword>BRAF Inhibitor</keyword>
	<keyword>melanoma</keyword>
	<keyword>MEK Inhibitor</keyword>
</DOC>